Actavis Warning Letter Adds Fuel To Pliva Takeover Battle
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr says FDA warning letter demonstrates Actavis’ inability to integrate acquisitions like Pliva.
You may also be interested in...
FDA Calls For Third-Party Auditor To Rectify Actavis Manufacturing Problems
Icelandic generics firm has received two warning letters concerning its New Jersey manufacturing plant.
FDA Calls For Third-Party Auditor To Rectify Actavis Manufacturing Problems
Icelandic generics firm has received two warning letters concerning its New Jersey manufacturing plant.
Door Opens For Barr To Acquire Pliva As Actavis Bows Out Of Bidding War
Hurdles for completing the acquisition still exist for Barr, which must acquire majority of Pliva shares.